Skip to main content

Advertisement

SpringerLink
Log in

The Efficacy of Triptans in Childhood and Adolescence Migraine

  • Childhood and Adolescent Headache (S Evers, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Studies on the acute treatment of migraine in children and adolescents are rare and difficult to design. In particular, the high placebo response in some trials makes it difficult to prove efficacy of a verum drug. All available placebo-controlled trials on the acute migraine treatment in children and adolescents with a triptan were analyzed with respect to different end points (rate of pain free and pain relief at 2 hours; rate of adverse events). We identified 6 crossover and 11 parallel group trials. Although the trials were heterogenous with respect to the triptans and the dosage, pooled data were calculated. The pooled responder rate of triptans for 2 hours pain free was 36.0 % in crossover trials (significant difference to placebo with 17.7 %) and 32.5 % in parallel group trials (significant difference to placebo with 26.3 %). Triptans also showed a significantly higher pain relief rate at 2 hours than placebo both in crossover and parallel group trials. The rate of adverse events was significantly higher after triptans than after placebo. However, triptans were well tolerated in all trials. At least 1 trial with significant efficacy was found for sumatriptan (10–20 mg nasal spray), zolmitriptan (2.5–5 mg tablet), rizatriptan (5–10 mg tablet), and almotriptan (12.5–25 mg tablet). Placebo rates for efficacy were considerably lower in crossover trials than in parallel group trials. This analysis suggests that parallel group trials on the acute treatment of migraine in children and adolescents with a triptan show a very low therapeutic gain because of a high placebo rate. The verum response rates, however, are very similar to those seen in adulthood trials. However, there is sufficient evidence that at least some triptans are efficacious even in childhood and adolescence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103–7.

    Article  PubMed  Google Scholar 

  2. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine headache. Headache. 2002;42:780–6.

    Article  PubMed  Google Scholar 

  3. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006;67:497–9.

    Article  PubMed  CAS  Google Scholar 

  4. Überall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology. 1999;52:1507–10.

    Article  Google Scholar 

  5. Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106:989–97.

    Article  PubMed  CAS  Google Scholar 

  6. Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in the treatment of migraine attacks in children. Neurology. 2004;62:883–7.

    Article  PubMed  CAS  Google Scholar 

  7. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. American Academy of Neurology. Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215–24.

    Article  PubMed  CAS  Google Scholar 

  8. Evers S, Kropp P, Pothmann R, Heinen F, Ebinger F. Therapie idiopathischer Kopfschmerzen im Kindes- und Jugendalter. Nervenheilkunde. 2008;27:1127–37.

    Google Scholar 

  9. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.

    Article  PubMed  CAS  Google Scholar 

  10. Lewis DW, Winner P, Wasiewski W. The placebo response rate in children and adolescents. Headache. 2005;45:232–9.

    Article  PubMed  Google Scholar 

  11. Winner P. Overview of pediatric headache. Curr Treat Options Neurol. 2004;6:471–87.

    Article  PubMed  Google Scholar 

  12. Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29:436–44.

    Article  PubMed  CAS  Google Scholar 

  13. Lewis DW, Winner P, Hershey AF, Wasiewski WW. Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120:390–6.

    Article  PubMed  Google Scholar 

  14. Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67:1135–40.

    Article  PubMed  CAS  Google Scholar 

  15. Hämäläinen M, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently than adults? Neurology. 1997;48:1100–3.

    Article  PubMed  Google Scholar 

  16. Winner P, Linder S, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache. 2007;47:511–8.

    Article  PubMed  Google Scholar 

  17. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46:101–9.

    Article  PubMed  Google Scholar 

  18. Winner P, Rothner D, Wooten J, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46:212–22.

    Article  PubMed  Google Scholar 

  19. Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48:1326–36.

    Article  PubMed  Google Scholar 

  20. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, et al. Rizatriptan protocol 059 and 061 study groups. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and 2 open-label, multiple-attack studies. Headache. 2004;44:891–9.

    Article  PubMed  Google Scholar 

  21. Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan Adolescence Study Group. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42:49.

    Article  PubMed  Google Scholar 

  22. Rothner A, Edwards K, Kerr L, Debussy S, Asgharnejad M. Efficacy and safety of naratriptan tablets in adolescent migraine. J Neurol Sci. 1997;150:S106.

    Article  Google Scholar 

  23. Korsgard AG. The tolerability, safety and efficacy of oral sumatriptan 50 mg and 100 mg for the acute treatment of migraine in adolescents (Abstract). Cephalalgia. 1995;15 Suppl 16:99.

    Google Scholar 

  24. • Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, et al. The Rizatriptan Protocol 082 Pediatric Migraine Study Group. Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32:750–65. This study presents a unique design (so-called enriched design) to avoid problems caused by the high placebo responses in childhood and adolescence migraine trials.

    Article  PubMed  Google Scholar 

  25. Winner P, Rothner AD, Putnam DG, Asgharnejad M. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trial’s database. Headache. 2003;43:451–7.

    Article  PubMed  CAS  Google Scholar 

  26. Derosier FJ, Lewis D, Hershey AD, Winner PK, Pearlman E, Rothner AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012;129:e1411–20.

    Article  PubMed  Google Scholar 

  27. MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache. 1994;34:581–2.

    Article  PubMed  CAS  Google Scholar 

  28. Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in the pediatric neurology office practice. Headache. 1996;36:419–22.

    Article  PubMed  CAS  Google Scholar 

  29. Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract. 2000;54:466–9.

    PubMed  CAS  Google Scholar 

  30. Macedo A, Farre M, Banos JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some characteristics of clinical trials. Eur J Pharmacol. 2006;62:161–72.

    Article  Google Scholar 

  31. Bendtsen L, Mattson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003;23:487–90.

    Article  PubMed  CAS  Google Scholar 

  32. Harth SC, Johnstone RR, Thong YH. The psychological profile of parents who volunteer their children for clinical research: a controlled study. J Med Ethics. 1992;18:86–93.

    Article  PubMed  CAS  Google Scholar 

  33. Caldwell PH, Butow PN, Craig JC. Parents' attitudes to children's participation in randomized controlled trials. J Pediatr. 2003;142:554–9.

    Article  PubMed  Google Scholar 

  34. Marziniak M, Haag G, May A, Lampl C, Sandor P, Diener HC, et al. Therapie des Kopfschmerzes bei Medikamentenübergebrauch. Nervenheilkunde. 2013;32:135–44.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Stefan Evers is a section editor for Current Pain and Headache Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Münster, Münster, Germany

    Stefan Evers

  2. Department of Neurology, Krankenhaus Lindenbrunn, Lindenbrunn 1, 31863, Coppenbrügge, Germany

    Stefan Evers

Authors
  1. Stefan Evers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Evers.

Additional information

This article is part of the Topical Collection on Childhood and Adolescent Headache

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evers, S. The Efficacy of Triptans in Childhood and Adolescence Migraine. Curr Pain Headache Rep 17, 342 (2013). https://doi.org/10.1007/s11916-013-0342-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-013-0342-y

Keywords

Search

Navigation